New indication extensions for vildagliptin for the treatment of type 2 diabetes

14.11.2012 11:03

For the treatment of type 2 diabetes, vildagliptin has received the “green light” from the European Medicines Agency (EMA) for two new indication expansions. Both in the monoform (Jalra®) and in the fixed combination with metformin (Icandra®), vildagliptin from the pharmaceutical company UCB can now be used as an add-on to insulin if diet and exercise in addition to a stable insulin dose do not lead to adequate glycemic control .

Furthermore, the triple combination with metformin and sulfonylurea can be used if diet and exercise in addition to dual therapy with these drugs cannot sufficiently lower blood sugar. This means that type 2 diabetes patients have new therapy options available that can help offer an effective therapy option at all stages of the disease.